“…4-PBA is an orally administrated short-chain fatty acid used regularly in treatment of urea cycle disorders [31]. 4-PBA has been shown, both in vitro and in vivo, to promote trafficking of mutant proteins [33,43,93,175,213,215,216,240,261,283,284], as well as to prevent protein aggregation [49], induce differentiation and maturation of malignant cells [6,134,247], influence lipid metabolism [121] and promote protein synthesis [3, 53,54], all with great impact on different types of diseases. The most well studied effect of 4-PBA is in restoring the cystic fibrosis conductance channel to the plasma membrane [213,290] and it has already been tested with some degree of success in human patients with cystic fibrosis [240,289].…”